Preterm birth (PTB) remains the leading cause of infant morbidity and mortality. Despite 50
years of research, therapeutic options are limited and many lack clear efficacy. Tocolytic …

In brief Preterm birth is the leading cause of perinatal morbidity and mortality; however,
current therapies offer limited efficacy to delay birth and improve neonatal outcomes. This …

Background Preterm birth is the leading cause of death in newborns and children. Tocolytic
drugs aim to delay preterm birth by suppressing uterine contractions to allow time for …

Preterm labour and delivery pose an increasing problem to the obstetrician. Improvements
in tocolysis with the recent introduction of new therapeutic targeting strategies, and a …

Background Preterm birth is a leading cause of neonatal mortality and morbidity, and
imposes high health and societal costs. Antenatal corticosteroids (ACS) to accelerate fetal …

The global rate of preterm delivery (before 37 completed weeks of pregnancy) is increasing
and there are no effective means available to prevent this rise. Prematurity is the principal …

Objective To determine the most effective tocolytic agent at delaying delivery. Design
Systematic review and network meta-analysis. Data sources Cochrane Central Register of …

Background Preterm birth represents the single largest cause of mortality and morbidity for
newborns and a major cause of morbidity for pregnant women. Tocolytic agents include a …

Tocolytics have been used for over 60 years for women with preterm labor, which ultimately
can lead to preterm birth (PTB). Diagnosing preterm labor is challenging, but use of …

Background Preterm birth-related complications are the leading cause of death in newborns
and children under 5. Health outcomes of preterm newborns can be improved with …